News

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and subgroup analysis from its recent Phase 3 COMPETE ...
Lehi, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, August 19, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to ...
Les patients considèrent toujours la blouse blanche des médecins comme un symbole de professionnalisme et de confiance.
Idorsia Ltd (SIX: IDIA) announces the end results of the repurchase offer for its outstanding CHF 204 *  million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350), and CHF 600 million ...
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi ...
Over the last couple of months, senior leaders from across the Coloplast Group have worked together to finalise the new Coloplast Group strategy, which will be communicated internally and externally ...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...
CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel ...
After extensive negotiations, Opthea has reached a binding agreement with the DFA Investors to terminate the DFA. As part of the settlement arrangements, all parties have entered into an agreement of ...
Oslo (Norway), 18 August 2025 – PCI Biotech Holding ASA (PCI Biotech, OSE:PCIB) today announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector ...
(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the ...
The stock options have a ten-year term and exercise prices ranging from $2.11 to $2.04 per share, which is equal to the closing price of Vor Bio’s common stock on the respective grant dates of the ...